Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2020-03-23 |
Soligenix (USA - NY) the University of Hawai?i at M?noa (USA) |
|
COVID-19, coronavirus infection |
research |
Infectious diseases |
Research agreement |
2020-02-26 |
Gemini Therapeutics (USA) - Singapore Eye Research Institute (SG) |
new targets associated with age-related macular degeneration |
Age-related Macular Degeneration (AMD), polypoidal choroidal vasculopathy |
R&D |
Ophthalmological diseases - Cardiovascular diseases |
Research agreement |
2020-02-12 |
Sangamo Therapeutics (USA - CA) |
member of the board |
|
nomination |
|
Nomination |
2019-12-23 |
Sangamo Therapeutics (USA - CA) Pfizer (USA - NY) |
gene therapy programs for hemophilia A, including SB-525 |
hemophilia A |
licensing - development - commercialisation |
Rare diseases - Genetic diseases - Hematological diseases |
Licensing agreement |
2019-11-26 |
Sangamo Therapeutics (USA - CA) |
member of the board |
|
nomination |
|
Nomination |
2019-11-08 |
Sangamo Therapeutics (USA - CA) |
scientific advisory board |
|
nomination |
|
Nomination |
2019-09-30 |
Sangamo Therapeutics (USA - CA) |
senior vice president, chief medical officer |
|
nomination |
|
Nomination |
2019-09-13 |
Gemini Therapeutics (USA) |
CEO |
|
nomination |
Rare diseases - Genetic diseases- Ophthalmological diseases |
Nomination |
2019-07-31 |
Sangamo Therapeutics (USA - CA) |
executive vice president and general counsel |
|
nomination |
|
Nomination |
2019-06-19 |
Genzyme (USA - MA), a Sanofi company (France) Voyager Therapeutics (USA - MA) |
gene therapy programs for Parkinson’s disease, Friedreich’s ataxia, Huntington’s disease and other CNS disorders |
Parkinson’s disease, Friedreich’s ataxia and Huntington’s disease and other CNS disorders |
development - commercialisation |
CNS diseases - Neurodegenerative diseases |
Development agreement |
2019-05-20 |
Voyager Therapeutics (USA-MA) |
head of R&D |
|
nomination |
Neurological diseases - Neurodegenerative diseases |
Nomination |
2019-04-02 |
Sangamo Therapeutics (USA - CA) Brammer Bio (USA - CA) |
large-scale AAV manufacturing |
|
manufacturing - production |
|
Production agreement |
2019-03-12 |
Sangamo Therapeutics (USA - CA) |
senior vice president cell therapy |
|
nomination |
|
Nomination |
2019-02-27 |
Sangamo Therapeutics (USA - CA) Biogen (USA - MA) |
ST-501, ST-502, and a neuromuscular target |
tauopathies including Alzheimer’s disease, synucleinopathies including Parkinson’s disease |
licensing - development - commercialisation |
Neurological diseases - Neurodegenerative diseases - Neuromuscular diseases |
Licensing agreement |
2019-02-22 |
Voyager Therapeutics (USA-MA) Abbvie (USA - IL) |
vectorized antibodies directed at pathological species of alpha-synuclein |
Parkinson's disease and diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein |
development - commercialisation |
Neurological diseases - Neurodegenerative diseases |
Development agreement |
2019-01-22 |
Voyager Therapeutics (USA-MA) |
general counsel |
|
nomination |
Neurological diseases - Neurodegenerative diseases |
Nomination |
2019-01-22 |
Voyager Therapeutics (USA-MA) Neurocrine Biosciences (USA - CA) |
VY-AADC, VY-FXN01 |
Parkinson’s Disease - Friedreich’s Ataxia |
development, commercialization |
Rare diseases - Neurological diseases - Neurodegenerative diseases |
Development agreement |
2019-01-15 |
Voyager Therapeutics (USA-MA) |
chief medical officer |
|
nomination |
Neurological diseases - Neurodegenerative diseases |
Nomination |
2019-00-22 |
Sangamo Therapeutics (USA - CA) |
vice president Research & Development (R&D) |
|
nomination |
|
Nomination |
2018-12-17 |
Voyager Therapeutics (USA-MA) The Michael J. Fox Foundation for Parkinson’s Research (MJFF) (USA) |
Parkinson’s Disease Education Consortium, Parkinson’s Progression Markers Initiative |
Parkinson's disease |
collaboration |
Neurological diseases - Neurodegenerative diseases |
Collaboration agreement |